These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

392 related items for PubMed ID: 29773553

  • 21. Role of dutasteride in pre-clinical ETS fusion-positive prostate cancer models.
    Ateeq B, Vellaichamy A, Tomlins SA, Wang R, Cao Q, Lonigro RJ, Pienta KJ, Varambally S.
    Prostate; 2012 Oct 01; 72(14):1542-9. PubMed ID: 22415461
    [Abstract] [Full Text] [Related]

  • 22. Expression of steroid and peptide hormone receptors, metabolic enzymes and EMT-related genes in prostate tumors in relation to the presence of the TMPRSS2/ERG fusion.
    Gerashchenko GV, Mevs LV, Chashchina LI, Pikul MV, Gryzodub OP, Stakhovsky EO, Kashuba VI.
    Exp Oncol; 2018 Jun 01; 40(2):101-108. PubMed ID: 29949537
    [Abstract] [Full Text] [Related]

  • 23. Induced chromosomal proximity and gene fusions in prostate cancer.
    Mani RS, Tomlins SA, Callahan K, Ghosh A, Nyati MK, Varambally S, Palanisamy N, Chinnaiyan AM.
    Science; 2009 Nov 27; 326(5957):1230. PubMed ID: 19933109
    [Abstract] [Full Text] [Related]

  • 24. ERG signaling in prostate cancer is driven through PRMT5-dependent methylation of the Androgen Receptor.
    Mounir Z, Korn JM, Westerling T, Lin F, Kirby CA, Schirle M, McAllister G, Hoffman G, Ramadan N, Hartung A, Feng Y, Kipp DR, Quinn C, Fodor M, Baird J, Schoumacher M, Meyer R, Deeds J, Buchwalter G, Stams T, Keen N, Sellers WR, Brown M, Pagliarini RA.
    Elife; 2016 May 16; 5():. PubMed ID: 27183006
    [Abstract] [Full Text] [Related]

  • 25. Relation of ETS transcription factor family member ERG, androgen receptor and topoisomerase 2β expression to TMPRSS2-ERG fusion status in prostate cancer.
    Kolar Z, Burdova A, Jamaspishvili T, Bouchal J, Kucerova R, Bienova M, Kral M, Student V.
    Neoplasma; 2014 May 16; 61(1):9-16. PubMed ID: 24195515
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Genetic interaction between Tmprss2-ERG gene fusion and Nkx3.1-loss does not enhance prostate tumorigenesis in mouse models.
    Linn DE, Bronson RT, Li Z.
    PLoS One; 2015 May 16; 10(3):e0120628. PubMed ID: 25780911
    [Abstract] [Full Text] [Related]

  • 29. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming.
    Iljin K, Wolf M, Edgren H, Gupta S, Kilpinen S, Skotheim RI, Peltola M, Smit F, Verhaegh G, Schalken J, Nees M, Kallioniemi O.
    Cancer Res; 2006 Nov 01; 66(21):10242-6. PubMed ID: 17079440
    [Abstract] [Full Text] [Related]

  • 30. N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer.
    Pflueger D, Rickman DS, Sboner A, Perner S, LaFargue CJ, Svensson MA, Moss BJ, Kitabayashi N, Pan Y, de la Taille A, Kuefer R, Tewari AK, Demichelis F, Chee MS, Gerstein MB, Rubin MA.
    Neoplasia; 2009 Aug 01; 11(8):804-11. PubMed ID: 19649210
    [Abstract] [Full Text] [Related]

  • 31. Calcium Channel Blocker Use and Risk of Prostate Cancer by TMPRSS2:ERG Gene Fusion Status.
    Geybels MS, McCloskey KD, Mills IG, Stanford JL.
    Prostate; 2017 Feb 01; 77(3):282-290. PubMed ID: 27753122
    [Abstract] [Full Text] [Related]

  • 32. Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer.
    Cai C, Wang H, Xu Y, Chen S, Balk SP.
    Cancer Res; 2009 Aug 01; 69(15):6027-32. PubMed ID: 19584279
    [Abstract] [Full Text] [Related]

  • 33. Loss of SLC45A3 protein (prostein) expression in prostate cancer is associated with SLC45A3-ERG gene rearrangement and an unfavorable clinical course.
    Perner S, Rupp NJ, Braun M, Rubin MA, Moch H, Dietel M, Wernert N, Jung K, Stephan C, Kristiansen G.
    Int J Cancer; 2013 Feb 15; 132(4):807-12. PubMed ID: 22821757
    [Abstract] [Full Text] [Related]

  • 34. [Frequency and transcript variant analysis of gene fusions between TMPRSS2 and ETS transcription factor genes in prostate cancer].
    Dai MJ, Chen LL, Zheng YB, Chen W, Tao ZH, Weng ZL, Wu XL, Li CD, Chen ZG, Chen XD, Shi SB.
    Zhonghua Yi Xue Za Zhi; 2008 Mar 11; 88(10):669-73. PubMed ID: 18642766
    [Abstract] [Full Text] [Related]

  • 35. 5' UTR control of native ERG and of Tmprss2:ERG variants activity in prostate cancer.
    Zammarchi F, Boutsalis G, Cartegni L.
    PLoS One; 2013 Mar 11; 8(3):e49721. PubMed ID: 23472063
    [Abstract] [Full Text] [Related]

  • 36. The prognostic and predictive value of TMPRSS2-ERG gene fusion and ERG protein expression in prostate cancer biopsies.
    Berg KD.
    Dan Med J; 2016 Dec 11; 63(12):. PubMed ID: 27910803
    [Abstract] [Full Text] [Related]

  • 37. Germline Genetic Variants Associated with Somatic TMPRSS2:ERG Fusion Status in Prostate Cancer: A Genome-Wide Association Study.
    Ma C, Wang X, Dai JY, Turman C, Kraft P, Stopsack KH, Loda M, Pettersson A, Mucci LA, Stanford JL, Penney KL.
    Cancer Epidemiol Biomarkers Prev; 2023 Oct 02; 32(10):1436-1443. PubMed ID: 37555839
    [Abstract] [Full Text] [Related]

  • 38. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.
    Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM.
    Science; 2005 Oct 28; 310(5748):644-8. PubMed ID: 16254181
    [Abstract] [Full Text] [Related]

  • 39. A novel four-color fluorescence in situ hybridization assay for the detection of TMPRSS2 and ERG rearrangements in prostate cancer.
    Qu X, Randhawa G, Friedman C, O'Hara-Larrivee S, Kroeger K, Dumpit R, True L, Vakar-Lopez F, Porter C, Vessella R, Nelson P, Fang M.
    Cancer Genet; 2013 Oct 28; 206(1-2):1-11. PubMed ID: 23352841
    [Abstract] [Full Text] [Related]

  • 40. In situ sequencing identifies TMPRSS2-ERG fusion transcripts, somatic point mutations and gene expression levels in prostate cancers.
    Kiflemariam S, Mignardi M, Ali MA, Bergh A, Nilsson M, Sjöblom T.
    J Pathol; 2014 Oct 28; 234(2):253-61. PubMed ID: 24931216
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.